Cangrelor decreases ischemia driven revascularization meta analysis

Cangrelor Reduces ischemia Motorist revascularization in Patients Undergoing percutaneous coronary Artery: Evidence in the Metaanalysis of randomized trials

Cangrelor is actually a fresh parenteral adenosine diphosphate P2Y12 receptor inhibitor using rapid, deep and reversible inhibition of platelet activity. Randomized controlled trials comparing cangrelor together with control were all selected. We used exactly the random-effects units to calculate the hazard ratio. Key efficacy outcome was ischemia-driven revascularization, also primary safety outcome was TIMI major bleeding in 4-8 hours.Three RCTs comprised an overall total of 25,107 participants. The impacts of both Cangrelor are different against comparators such as MI and also all-cause mortality. But, cangrelor somewhat reduced the chance of ischemia-driven revascularization, Stent thrombosis and also Q wave MI without inducing a growth in acute or lifethreatening GUSTO bleeding or TIMI major bleeding. Separate investigation against just clopidogrel also revealed similar findings except q-wave MI outcome. Usage of cangrelor throughout PCI may possibly lessen the danger of ischemia-driven revascularization along with stent thrombosis, without inducing growth in severe bleeding.


Our most popular topics on Managedcaremag.com